The widespread clinical adoption of GLP-1 receptor agonists is reshaping financial projections across health insurance providers and regional medical systems.
Long-Term Claims Trajectory
Underwriters report early reductions in cardiovascular intervention claims among patients on GLP-1 therapy. However, short-term pharmaceutical spending increases present balance sheet challenges for self-insured corporate employer plans.